COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Income Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare income growth against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.

Revenue Growth

4.52%

Increased from previous period

Growth of 4.52% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

4.63%

Increased from previous period

Cost growth exceeding 1.5x Healthcare median of 1.21%. Jim Chanos would check for structural cost disadvantages.

Gross Profit Growth

4.09%

Increased from previous period

Growth of 4.09% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

-0.41%

Decreased from previous period

Margin decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

-1.93%

Increased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

5.27%

Increased from previous period

Operating expenses growth exceeding 1.5x Healthcare median of 0.49%. Jim Chanos would check for waste.

Total Costs & Expenses Growth

4.73%

Increased from previous period

Total costs growth exceeding 1.5x Healthcare median of 2.77%. Jim Chanos would check for waste.

Interest Expense Growth

155.56%

Increased from previous period

Interest expense change of 155.56% versus flat Healthcare costs. Walter Schloss would verify control.

Depreciation & Amortization Growth

6.48%

Increased from previous period

D&A change of 6.48% versus flat Healthcare D&A. Walter Schloss would verify adequacy.

EBITDA Growth

-10.56%

Increased from previous period

EBITDA decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EBITDA Margin Growth

-14.43%

Increased from previous period

EBITDA margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Income Growth

-1.75%

Decreased from previous period

Operating income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Margin Growth

-6.00%

Decreased from previous period

Operating margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Other Income/Expenses Growth

-98.31%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

-10.91%

Decreased from previous period

Pre-tax income decline while Healthcare median is -1.22%. Seth Klarman would investigate causes.

Pre-Tax Margin Growth

-14.76%

Decreased from previous period

Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

-76.99%

Decreased from previous period

Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Net Income Growth

23.00%

Increased from previous period

Income change of 23.00% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

17.68%

Increased from previous period

Margin change of 17.68% versus flat Healthcare. Walter Schloss would verify quality.

EPS Growth

22.99%

Increased from previous period

EPS change of 22.99% versus flat Healthcare. Walter Schloss would verify quality.

Diluted EPS Growth

22.99%

Increased from previous period

Diluted EPS change of 22.99% versus flat Healthcare. Walter Schloss would verify quality.

Share Count Growth (Basic)

0.00%

Decreased from previous period

Share count reduction exceeding 1.5x Healthcare median of 0.04%. Joel Greenblatt would investigate strategy.

Share Count Growth (Diluted)

0.00%

Decreased from previous period

Diluted share reduction exceeding 1.5x Healthcare median of 0.01%. Joel Greenblatt would investigate strategy.

Select Chart Metric:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Revenue Growth

4.52%

Increased from previous period

Growth of 4.52% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

4.63%

Increased from previous period

Cost growth exceeding 1.5x Healthcare median of 1.21%. Jim Chanos would check for structural cost disadvantages.

Gross Profit Growth

4.09%

Increased from previous period

Growth of 4.09% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

-0.41%

Decreased from previous period

Margin decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

-1.93%

Increased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

5.27%

Increased from previous period

Operating expenses growth exceeding 1.5x Healthcare median of 0.49%. Jim Chanos would check for waste.

Total Costs & Expenses Growth

4.73%

Increased from previous period

Total costs growth exceeding 1.5x Healthcare median of 2.77%. Jim Chanos would check for waste.

Interest Expense Growth

155.56%

Increased from previous period

Interest expense change of 155.56% versus flat Healthcare costs. Walter Schloss would verify control.

Depreciation & Amortization Growth

6.48%

Increased from previous period

D&A change of 6.48% versus flat Healthcare D&A. Walter Schloss would verify adequacy.

EBITDA Growth

-10.56%

Increased from previous period

EBITDA decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EBITDA Margin Growth

-14.43%

Increased from previous period

EBITDA margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Income Growth

-1.75%

Decreased from previous period

Operating income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Margin Growth

-6.00%

Decreased from previous period

Operating margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Other Income/Expenses Growth

-98.31%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

-10.91%

Decreased from previous period

Pre-tax income decline while Healthcare median is -1.22%. Seth Klarman would investigate causes.

Pre-Tax Margin Growth

-14.76%

Decreased from previous period

Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

-76.99%

Decreased from previous period

Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Net Income Growth

23.00%

Increased from previous period

Income change of 23.00% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

17.68%

Increased from previous period

Margin change of 17.68% versus flat Healthcare. Walter Schloss would verify quality.

EPS Growth

22.99%

Increased from previous period

EPS change of 22.99% versus flat Healthcare. Walter Schloss would verify quality.

Diluted EPS Growth

22.99%

Increased from previous period

Diluted EPS change of 22.99% versus flat Healthcare. Walter Schloss would verify quality.

Share Count Growth (Basic)

0.00%

Decreased from previous period

Share count reduction exceeding 1.5x Healthcare median of 0.04%. Joel Greenblatt would investigate strategy.

Share Count Growth (Diluted)

0.00%

Decreased from previous period

Diluted share reduction exceeding 1.5x Healthcare median of 0.01%. Joel Greenblatt would investigate strategy.

Select Chart Metric: